Received Oct 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4D333 | — |
Pediatric dose to adult patient; on September 23rd 2025 they gave Engerix-B pediatric dose instead of Heplisav-B adult dose to an adult patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 24-year-old female patient who received HBV (Engerix B Junior) (batch number 4D333, expiry date 14-AUG-2026) for prophylaxis. Previously administered products included Hepatitis B (Patient received 2 prior Hepatitis B doses, on March 15th 2024 (unknown brand name, dosage or lot number, patient was living in a different country at that time)) and Heplisav B (Heplisav-B (lot number 944918, expiration date November 19th 2026) adult dose on August 29th 2024.). On 23-SEP-2025, the patient received Engerix B Junior. On 23-SEP-2025, an unknown time after receiving Engerix B Junior, the patient experienced adult use of a child product (Verbatim: Pediatric dose to adult patient) and underdose (Verbatim: on September 23rd 2025 they gave Engerix-B pediatric dose instead of Heplisav-B adult dose to an adult patient). The outcome of the adult use of a child product and underdose were not applicable.